Cedars-sinai Medical Center

Prometheus Biosciences, Inc.

Dalin Li

Stephan R Targan

Dermot McGovern

Janine M Bilsborough

Dermot P Mcgovern

Laurens Kruidenier

Mahyar Sabripour

Janine Bilsborough

David Q Shih

Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.

Methods of enriching or amplifying nucleic acids in a sample from a patient with inflammatory bowel disease

Methods of selecting, based on polymorphisms, an inflammatory bowel disease subject for treatment with an anti-TL1A antibody

The aspects disclosed herein describe methods of identifying a subject that is non-responsive to anti-TNF therapy. The aspects disclosed herein further provide for a method of selecting a therapy for a subject with Inflammatory Bowel Disease (IBD), and treating the subject with the therapy.

Kit comprising contiguous nucleobases, including position 76, of RS5745994

The present invention describes a method of prognosing high or low probability of developing an inflammatory bowel disease (IBD) in a subject and a method of diagnosing an inflammatory bowel disease (IBD) in a subject. The invention further provides for a method of identifying genes/genetic loci associated with a disease condition, such as IBD, CD and/or UC.

Diagnosis of inflammatory bowel disease based on genes

The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.

Mitigation and reversal of intestinal fibrosis and inflammation by inhibition of TL1A function

Method of enriching a target nucleic acid at a TNFRSF1B gene locus in a sample from a subject with inflammatory bowel disease

Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A)

Treatment and reversal of fibrosis and inflammation by inhibition of the TL1A-DR3 signaling pathway

Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease

Growing community of inventors

Walnut, CA, United States of America

Dalin Li